

## Disclosure of received notification

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received the following notification.

### Notification of Adrianus van Herk, received on 28 August 2018

- On 28 August 2018, Fagron received a notification that the shareholding of Adrianus van Herk, a person that notifies alone, had fallen below the disclosure threshold of 3% on 27 August 2018 as the result of the disposal of voting securities or voting rights.
- The notification of Adrianus van Herk can be viewed on [investors.fagron.com](https://investors.fagron.com) via this [link](#).

*In case of differences between the English translation and the Dutch original of this press release, the latter will prevail.*

### For more information

Constantijn van Rietschoten  
Chief Communications Officer  
Tel. +31 6 53 69 15 85  
[constantijn.van.rietschoten@fagron.com](mailto:constantijn.van.rietschoten@fagron.com)  
[investors.fagron.com](https://investors.fagron.com)

### Fagron profile

Fagron is a leading global company active in pharmaceutical compounding and focused on delivering personalized pharmaceutical care to hospitals, pharmacies, clinics and patients in 35 countries worldwide.

The Belgian company Fagron NV is located in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam (stock market code 'FAGR'). The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

